Injections: Clinical Trials

595 trials of Injections, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

182 completed, 162 recruiting, 87 unknown, 59 not yet recruiting. 595 Phase 2, 177 Phase 1, 42 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2595Completed 182, Recruiting 162, Unknown 87, Not yet recruiting 59, Terminated 47, Active not recruiting 33, Withdrawn 17, Enrolling by invitation 5, Suspended 3
Phase 1177Recruiting 64, Completed 39, Unknown 24, Not yet recruiting 18, Terminated 12, Active not recruiting 11, Withdrawn 6, Enrolling by invitation 2, Suspended 1
Phase 342Completed 13, Recruiting 11, Unknown 6, Not yet recruiting 4, Terminated 4, Active not recruiting 2, Enrolling by invitation 2

Follow Injections: new trials by email Literature Review of Injections trials Research Report on Injections

Trials (filtered) newest first · largest first

All 595 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial
Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Ceftriaxone for Injection, Amoxicillin - Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection
Phase 2Not yet recruitingThe University of Queensland3002027-04-012026-03-20
A Trial Evaluating the Anti-tumor Activity of Antibody-based Therapies in Metastatic Cancer Patients
Trastuzumab Deruxtecan for Injection (T-DXd) - NSCLC (Advanced Non-small Cell Lung Cancer), Urothelial Cancer
Phase 2Not yet recruitingCentre Leon Berard2002027-02-012026-11-13
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)
Azacitidine, Bone Marrow Aspiration and Biopsy, Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Phase 2Not yet recruitingNational Cancer Institute (NCI)1842027-01-042026-10-01
A Clinical Study of MHB034C for Injection in Participants With Advanced Solid Tumors
MHB034C for Injection - Advanced Malignant Solid Tumor
Phase 1 / Phase 2Not yet recruitingMinghui Pharmaceutical (Shanghai) LTD4002026-12-202026-11-10
PRP Versus NP Injections for Chronic Discogenic Low Back Pain
Platelet-Rich Plasma (PRP) Injection, Nucleus Pulposus (NP) Injection - Discogenic Low Back Pain
Phase 2 / Phase 3Not yet recruitingWalter Reed National Military Medical Center602026-12-012026-11-02
Clinical Trial of GenSci136 in Patients With Myasthenia Gravis
GenSci136 for injection - Patients With MG (gMG and oMG)
Phase 1 / Phase 2Not yet recruitingChangchun GeneScience Pharmaceutical Co., Ltd.722026-12-012026-11-13
FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)
Oxaliplatin, 5-Fluorouracil, Levofolinic Acid For Injection - Metastatic Colorectal Cancer (CRC)
Phase 2Not yet recruitingSun Yat-sen University2292026-11-012026-10-16
A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Colorectal Cancer Expressing HER2
Trastuzumab Rezetecan (SHR-A1811) injection; high dose, Trastuzumab Rezetecan (SHR-A1811) injection; low dose - Advanced Colorectal Cancer Expressing HER2
Phase 2Not yet recruitingJiangsu HengRui Medicine Co., Ltd.482026-11-012026-09-01
A Study of MBS314 for Injection in Participants With Relapsed/Refractory Multiple Myeloma.
MBS314 for Injection - Multiple Myeloma
Phase 1 / Phase 2Not yet recruitingBeijing Mabworks Biotech Co., Ltd.782026-11-012026-11-04
RC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ Adenocarcinoma
RC118(Dose 1) plus RC148(Dose 1), RC118(Dose 1) plus RC148(Dose 2), RC118(Dose 2) plus RC148(Dose 1) - Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 2 / Phase 3Not yet recruitingRemeGen Co., Ltd.6802026-11-012026-11-13
A Study of RT036 in Patients With Advanced Solid Tumors
RT036 for injection - Advanced Malignant Solid Tumours
Phase 1 / Phase 2Not yet recruitingShanghai Ruotuo Biosciences Co., Ltd.3082026-10-302026-09-28
A Study of hBMMSC Injection in Patients With aPAP
The human Bone Marrow Mesenchymal Stem Cell (hBMMSC) injection, Lactated Ringer's Injection (crystalloid) - Autoimmune Pulmonary Alveolar Proteinosis
Phase 2Not yet recruitingJiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.702026-10-302026-10-22
A Phase 2b Study to Evaluate the Efficacy, Safety, and PK Profiles of TNP-2092 Administered Via IA Injection in PJI Participants
TNP-2092 for injection, Vancomycin Hydrochloride for Injection, Oral antibiotics - Prosthetic Joint Infection (PJI)
Phase 2RecruitingTenNor Therapeutics (Zhongshan) Limited402026-10-212026-10-28
A Phase I/II of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors
LM-364 for injection, Tislelizumab - Advanced Solid Tumor Cancer
Phase 1 / Phase 2Enrolling by invitationLaNova Medicines Limited902026-10-202026-11-10
A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
HS-20093 for Injection, Adebrelimab Injection - Non-Small Cell Lung Cancer
Phase 2RecruitingHansoh BioMedical R&D Company762026-10-082026-10-23
Retlirafusp Alfa Combined With Zeprumetostat, Apatinib, and Chemotherapy as First-Line Treatment for Metastatic GC/GEJC
Retlirafusp alfa, zeprumetostat, apatinib - Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Phase 2Not yet recruitingFudan University552026-10-012026-10-14
Alleviating Suicidality by Combining Psychotherapy and IM Ketamine for Rapid Treatment in the Emergency Department
Ketamine Injectable Solution, Placebo Injection, Crisis Response Plan - Suicidal Ideation
Phase 2RecruitingThe University of Texas Health Science Center at San Antonio2002026-09-302026-10-15
A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma
LBL-024 for Injection, Bevacizumab injection, Oxaliplatin injection - Metastatic Colorectal Carcinoma
Phase 1 / Phase 2RecruitingNanjing Leads Biolabs Co.,Ltd3692026-09-282026-10-16
Phase 1/2 Clinical Study of HY07121 for Injection (Subcutaneous) in Patients With Advanced Solid Tumors
Test Product HY07121 for Injection (Subcutaneous) - Safety, Tolerability
Phase 1 / Phase 2Not yet recruitingSichuan Huiyu Pharmaceutical Co., Ltd2542026-09-082026-08-27
A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)+Bevacizumab injection, TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets) - Colorectal Cancer
Phase 1 / Phase 2RecruitingChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.712026-09-032026-09-22

Showing 20 of 595. Sign in to see all of them.

Conditions studied

Leukemia, Myeloid, Acute (36)  ·  Breast Neoplasms (23)  ·  Carcinoma, Non-Small-Cell Lung (20)  ·  Myelodysplastic Syndromes (14)  ·  Sarcoma (11)  ·  Stomach Neoplasms (11)  ·  COVID-19 (10)  ·  Neoplasms (10)  ·  Carcinoma, Hepatocellular (9)  ·  Leukemia, Myelomonocytic, Chronic (9)  ·  Melanoma (9)  ·  Multiple Myeloma (9)  ·  Pain, Postoperative (9)  ·  Ischemic Stroke (8)  ·  Lung Neoplasms (8)

Sponsors

RemeGen Co., Ltd. (18)  ·  Chinese PLA General Hospital (15)  ·  Nanjing Leads Biolabs Co.,Ltd (14)  ·  M.D. Anderson Cancer Center (12)  ·  CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (11)  ·  Suzhou Zelgen Biopharmaceuticals Co.,Ltd (11)  ·  Jiangsu HengRui Medicine Co., Ltd. (9)  ·  National Cancer Institute (NCI) (9)  ·  Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (8)  ·  Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (7)  ·  Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (7)  ·  Fred Hutchinson Cancer Center (6)  ·  GE Healthcare (6)  ·  Minghui Pharmaceutical (Hangzhou) Ltd (6)  ·  Sun Yat-sen University (6)

Countries

China (263)  ·  United States (181)  ·  France (21)  ·  Germany (18)  ·  Canada (15)  ·  Spain (14)  ·  United Kingdom (12)  ·  Australia (10)  ·  Netherlands (8)  ·  Russia (8)  ·  South Korea (8)  ·  Belgium (7)  ·  Egypt (7)  ·  Italy (7)  ·  Poland (6)

Top investigators

Jason Wu (9)  ·  Weidong Han, Ph.D (6)  ·  Hejian Zou (3)  ·  Lin Shen (3)  ·  Mark Nestor, MD (3)  ·  Ruihua Xu (3)  ·  Seonjun Bae, MD, PhD (3)  ·  Anna Halpern (2)  ·  Brenda LaTowsky, MD (2)  ·  Jianmin Fang, Ph.D (2)  ·  Jun Guo, Ph.D (2)  ·  Lei Zhang, Ph.D (2)

Results publications

PMID 34473343, PMID 36184192, PMID 37988648, PMID 41637644, PMID 10811675, PMID 11784875, PMID 11870177, PMID 11981766, PMID 12049862, PMID 12091661, PMID 12540794, PMID 16043828, PMID 16425523, PMID 17167137, PMID 17242396, PMID 17342504, PMID 17585221, PMID 19410716, PMID 19439093, PMID 20375404, PMID 20850390, PMID 21487286, PMID 21784508, PMID 21879261, PMID 22646630, PMID 23224215, PMID 23461895, PMID 24193798, PMID 24531850, PMID 24565698, PMID 24581682, PMID 24727841, PMID 25016003, PMID 25187512, PMID 25213161, PMID 25503156, PMID 25708147, PMID 25926350, PMID 25981818, PMID 26060065, PMID 26096650, PMID 26233808, PMID 26314234, PMID 26579854, PMID 26755520, PMID 26765068, PMID 26785742, PMID 26880867, PMID 27390310, PMID 27567243

NIH funding

2019 (5), 2023 (5), U10CA180888 (3), 2014 (2), 2025 (2), P30CA015704 (2), U10CA031946 (2), U10CA180821 (2), U10CA180886 (2), 2008 (1), 2015 (1), 2016 (1), 2018 (1), N01CM00070 (1), N01CM62201 (1)